Influenza vaccine (A/H3N2, A/H1N1, and B strains)

Phase 3

GSK plc (GSK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

12 competitors in Influenza

RHHBYRoche influenza treatment

MRNAmRNA Flu vaccine

SNYA/H1N1 pandemic influenza vaccine (non- adjuvanted)

Phase 3

BNTXInfluenza and COVID-19 Combination A

Phase 3

BNTXInvestigational COVID-19 Vaccine

Phase 2

View Full Landscape

Drug Information

Target Indication

Influenza

Clinical Trial

NCT00380211

Last updated: 10/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3

Infections, Meningococcal

62.5/25mcgPhase 3

Pulmonary Disease, Chronic Obstructive

FluoridePhase 3

Dental Caries

Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3

Haemophilus Influenzae Type b

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts